Last reviewed · How we verify

NCT06365905

Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding

Recruiting now Last updated 18 July 2025
What this trial tests

trial testing Non-Interventional Study in Endometrial Carcinoma in 300 participants. Currently enrolling.

Timeline
27 March 2024
Primary endpoint
30 June 2027
30 June 2027

Quick facts

Lead sponsorMayo Clinic
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment300
Start date27 March 2024
Primary completion30 June 2027
Estimated completion30 June 2027
Sites3 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

55 and older, female only, with Endometrial Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates if AI can be used with transvaginal ultrasound images for early detection of endometrial cancer or premalignant lesions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Non-Interventional Study

Trials testing the same drug.

Other recruiting trials for Endometrial Carcinoma

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06365905.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing